[10] [2] The medication also slows gastric emptying and acts on central appetite centers in the hypothalamus, leading to reduced caloric intake and subsequent weight loss
Kavanagh DH, Tansey KE, O'Donovan MC, Owen MJ
Takahashi RN, Pamplona FA, Prediger RD
Medicaid coverage of GLP-1 receptor agonists for weight loss remains inconsistent nationwide, with approximately 40% of state programs covering these medications only for type 2 diabetes management rather than standalone weight reduction
ELAV-like protein 1 (ELAVL1), encoding the RNA-binding protein HuR, has been shown to induce pyroptosis in cardiomyocytes under hyperglycemic conditions, and recent data revealed that upregulated ELAVL1 induced classical ferroptosis events [283, 284]